AuraSense Therapeutics' uniquely engineered Spherical Nucleic Acid (SNA™) constructs possess unparalleled biocompatibility and versatility as therapeutics. They hold great promise for combating the most threatening diseases, including heart disease, cancer, skin conditions and bacterial infection.
SNA™ constructs overcome one of the most difficult obstacles to gene regulation: safe and effective delivery into cells and tissues. SNA™ constructs exhibit high stability, high binding specificity, and unparalleled transfection efficiency into numerous cell and tissue types. Needing no carriers or transfection agents, they provoke minimal immune response and no known toxicity.
SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. The Company's scientific founders and their developments have been the subject of over 80 international and national awards, over 500 publications, and over 450 patents. AuraSense Therapeutics is a subsidiary of AuraSense, LLC.
Chad Mirkin to Receive Linus Pauling Medal Award
Chad Mirkin Named Entrepreneur of the Year
Nanoparticles: The Next Big Thing in Medicine
Journal NATURE Highlights SNA Platform in "Biomedicine: The New Gold Standard"
Sergei Gryaznov PhD Joins AuraSense Therapeutics as Chief Technology Officer